Phase II evaluation of dalantercept, a soluble recombinant activin receptor-like kinase 1 (ALK1) receptor-fusion protein, for treatment of recurrent/persistent endometrial cancer: GOG-0229N Meeting Abstract
| Authors: | Makker, V.; Filiaci, V. L.; Chen, L. M.; Darus, C.; Kendrick, J. E.; Sutton, G.; Moxley, K.; Aghajanian, C. |
| Abstract Title: | Phase II evaluation of dalantercept, a soluble recombinant activin receptor-like kinase 1 (ALK1) receptor-fusion protein, for treatment of recurrent/persistent endometrial cancer: GOG-0229N |
| Meeting Title: | 50th Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 32 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2014 May 30-Jun 3 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2014-05-20 |
| Language: | English |
| ACCESSION: | WOS:000358613203578 |
| PROVIDER: | wos |
| DOI: | 10.1200/jco.2014.32.15_suppl.5594 |
| Notes: | Meeting Abstract: 5594 -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
-
263Makker -
607Aghajanian
Related MSK Work